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Abstract
This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor
of vascular endothelial growth factor and epidermal growth factor receptor, on paclitaxel (PTX) tumor distribution and
antitumor activity in xenograft models of human ovarian carcinoma. Nude mice bearing A2780-1A9 xenografts re-
ceived daily (5, 10, or 15 days) doses of vandetanib (50 mg/kg per os), combined with PTX (20 mg/kg intravenously).
Morphologic and functional modifications associated with the tumor vasculature (CD31 and α-smooth muscle actin
staining and Hoechst 33342 perfusion) and PTX concentrations in plasma and tumor tissues were analyzed. Activity
was evaluated as inhibition of tumor growth subcutaneously and spreading into the peritoneal cavity. Vandetanib
treatment produced no significant change in tumor vessel density, although a reduced number of large vessels, an
increased percentage of mature vessels, and diminished tumor perfusion were evident. Pretreatment with vandetanib
led to decreased tumor PTX levels within 1 hour of PTX injection, although 24 hours later, tumor PTX levels were
comparable with controls. In efficacy studies, the combination of vandetanib plus PTX improved antitumor activity
compared with vandetanib or PTX alone, with greater effects being obtained when PTX was administered before
vandetanib. The combination of PTX plus vandetanib reduced tumor burden in the peritoneal cavity of mice and sig-
nificantly increased their survival. Analysis of vascular changes and PTX tumor uptake in vandetanib-treated tumors
may help to guide the scheduling of vandetanib plus PTX combinations and may have implications for the design of
clinical trials with these drugs.
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Introduction
Angiogenesis plays a critical role in sustaining the growth of solid
tumors and in promoting tumor metastasis [1,2]. Furthermore, the
tumor vasculature may also influence the delivery and effectiveness of
anticancer therapy [3,4]. Drugs targeting the tumor vasculature have
been developed and have shown efficacy in preclinical models and,
more recently, in clinical studies in several solid tumor types [2,5,6].
In general, antiangiogenic agents have provided only modest ben-
efit as monotherapy, and therefore, they have been evaluated ex-
tensively in combination with conventional chemotherapies [7,8]. For
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example, bevacizumab, a monoclonal antibody directed against vascular
endothelial growth factor (VEGF), is currently approved for treatment
of metastatic colorectal cancer, non–small cell lung cancer (NSCLC)
and breast cancer, in combination with standard-of-care chemotherapy
[9,10]. However, the mechanism by which antiangiogenic agents in-
crease the efficacy of chemotherapy is not well understood.
In many cases, combination schedules are chosen empirically. To
optimize the combination approaches used in the clinic, a more ra-
tional approach to combination selection may be needed, which
takes into account the mechanistic and pharmacokinetic interactions
of the drugs as well as the biologic modification of the tumor micro-
environment [11].
Combination therapy with an antiangiogenic agent plus chemo-
therapy acts at multiple targets within the tumor, depriving it of nu-
trients and oxygen (i.e., antivascular and antiangiogenic effects) and
killing highly proliferative tumor cells (i.e., cytotoxic effect) [12].
This might seem paradoxical because by modifying the tumor vascu-
lature, antiangiogenic therapy could potentially impair the delivery of
cytotoxic drugs [13].
However, the tumor vasculature is characterized by increased vessel
permeability, dilatation, and tortuosity, decreased pericyte coverage,
and abnormal basement membranes due to an imbalance between
proangiogenic and antiangiogenic factors [14–16]. As a consequence,
tumor blood flow is impaired, and this, together with compression of
the blood vessels by cancers cells, can result in high interstitial fluid
pressure, hypoxic regions within the tumor, and ultimately impaired
drug delivery [17,18]. Recently, Jain [19] hypothesized that during
antiangiogenic therapy (in particular, anti-VEGF therapy), a tempo-
rally defined “window” exists during which abnormal tumor blood
vessels become morphologically “normalized,” theoretically leading to
improved blood flow and increased delivery of chemotherapy and
oxygen to the tumor.
Changes in the tumor microenvironment, such as decreased micro-
vessel density and vessel area, increased pericyte coverage, decreased
interstitial fluid pressure, and hypoxia, after anti-VEGF therapy have
been demonstrated by several investigators [20–23]. However, whether
these morphologic changes are accompanied by functional modifica-
tions, such as improved drug and oxygen delivery, remains contro-
versial [24,25]. Moreover, it has not been clearly demonstrated how
an improvement in drug penetration translates into an increase in
therapeutic response [22,23]. The presence of a “normalization” win-
dow may necessitate finely tuned scheduling and sequencing of anti-
angiogenic and cytotoxic combination therapies, although this would
present significant practical challenges in the clinical setting.
Several receptor tyrosine kinase inhibitors (RTKIs) that target
VEGF receptors (VEGFRs) as well as other growth factor receptor sig-
naling pathways relevant in tumor progression are under development
[7,26,27]. These agents not only directly affect tumor vasculature but
also have supplemental activity on other compartments of the tumor
stroma and on tumor cells themselves. Improved antitumor efficacy
has been reported after their addition to chemotherapy in experimen-
tal tumor models [2,7,11,28]. Vandetanib (Zactima; AstraZeneca,
Macclesfield, UK) is an orally available, small-molecule inhibitor of
VEGFR-2, epidermal growth factor receptor (EGFR), and rearranged
during transfection tyrosine kinases [29,30]. Effects on tumor vas-
culature have been described in preclinical studies with vandetanib,
including reduced vascular density [30,31], decreased endothelial cell
proliferation associated with apoptosis [32,33], and decreased vascular
permeability [31]. In preclinical tumor models, vandetanib has shown
activity as a single agent [29,30,32,33] and enhanced the activity of
chemotherapy and radiotherapy [34–37].
Vandetanib is being investigated in phase 3 clinical trials in second-
line NSCLC and in phase 2 trials in various tumor types including
metastatic hereditary medullary thyroid cancer [38]. Recently, a ran-
domized phase 2 study of vandetanib plus paclitaxel (PTX) and car-
boplatin as first-line treatment of advanced NSCLC demonstrated
prolongation of progression-free survival with this triple regimen com-
pared with PTX plus carboplatin [39]. PTX alone or in combination
with carboplatin is currently used as a standard treatment in ovarian
carcinoma [40].
On this ground, we decided to investigate the influence of vandetanib
on the antitumor activity of PTX in a preclinical model of ovarian
carcinomas. For this purpose, A2780-1A9 human ovarian carcinoma
xenografts, previously characterized for angiogenic phenotype and re-
sponse to PTX alone and in combination with angiogenesis inhibitors,
have been used [41–43]. Modifications in the tumor vasculature and
in tumor uptake of PTX after vandetanib treatment were investigated,
and the results were used to rationalize the combination regimen.
Materials and Methods
Drug Preparations
Vandetanib (AstraZeneca) was suspended in 1% Tween-80 (Sigma,
Milan, Italy) by gentle shaking with 4-mm glass beads at room tem-
perature overnight, and the suspension used within 1 week of prepa-
ration. Vandetanib was administered by daily oral gavage at a dose of
50 mg/kg. Paclitaxel (PTX; kindly provided by Indena S.p.A., Milan,
Italy) was dissolved in 50% Cremophor EL (Sigma) and 50% ethanol
and further diluted with saline immediately before use. PTX was ad-
ministered intravenously (i.v.) at a dose of 20 mg/kg. Control mice
received the corresponding vehicle.
Animals and Xenograft Tumor Model
Six- to eight-week-old female NCr-nu/numice were obtained from
Harlan (Correzzana, Italy). Mice were maintained under specific
pathogen-free conditions, housed in isolated vented cages, and han-
dled using aseptic procedures. Procedures involving animals and their
care were conducted in conformity with institutional guidelines that
are in compliance with national (Legislative Decree 116 of January
27, 1992, Authorization n.169/94-A issued December 19, 1994, by
Ministry of Health) and international laws and policies (EEC Coun-
cil Directive 86/609, OJ L 358. 1, December 12, 1987; Standards
for the Care and Use of Laboratory Animals, United States National
Research Council, Statement of Compliance A5023-01, November
6, 1998). A2780-1A9 human ovarian carcinoma cells (10 × 106)
were implanted subcutaneously in the flank or into the peritoneal
cavity of nude mice.
Vessel Analysis after Vandetanib Treatment
A2780-1A9 tumor-bearing mice (n = 5; tumor weight approxi-
mately 150 mg) were treated with vandetanib or its vehicle for 5
to 15 days. One minute before killing, mice were perfused with
40 mg/kg i.v. Hoechst 33342 (Sigma). Tumors were excised and
divided into two parts: one half was embedded in optimal cutting
compound, snap-frozen, and stored at −80°C for immunohistochem-
ical analyses of CD31 (vessel density and morphology), α-smooth
muscle actin (α-SMA; vessel maturation), and vessel perfusion; the
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other half was immediately frozen at −80°C for HPLC analysis of
Hoechst 33342. Tumor tissues were processed as described in Sup-
plementary Information 1.
Pharmacokinetic Analysis
A2780-1A9 tumor-bearing mice (n = 4; tumor weight approxi-
mately 150 mg) were pretreated with vandetanib or its vehicle for
5, 10, or 15 days as detailed in the Results section. Four hours after
the last vandetanib (or its vehicle) dose, PTX was administered. Tu-
mor and plasma samples were collected at different time points (15
and 30 minutes and 1, 3, 6, and 24 hours) after PTX treatment. At
the indicated sampling time, mice were anesthetized, blood was
collected from retro-orbital plexus into heparinized tubes, and the
plasma fraction was separated. Mice were killed by cervical disloca-
tion, and tumors excised and snap frozen. Analysis of the samples
was performed by HPLC with UV detection at 230 nm as described
in Supplementary Information 2. Noncompartmental pharmaco-
kinetic parameters were estimated by WinNonlin Pro Node 4.1
pharmacokinetic software (Pharsight Co. Mountain View, CA).
Assessment of Antitumor Response to Vandetanib and PTX
Mice bearing A2780-1A9 were treated with vandetanib, PTX,
vandetanib plus PTX, or vehicle according to two experimental pro-
tocols. In the first protocol (Figure 5), mice were pretreated with
vandetanib for 1, 5, or 10 days and randomized to received a single
dose of PTX at approximately 150 mg of tumor weight; for the 5-day
schedule of vandetanib, a parallel group of mice was also established
to receive vandetanib after PTX. In the second protocol (Figure 6),
treatment schedules (5 days vandetanib/1 dose of PTX) were repeated
for three cycles, with a 5-day break between cycles. The combination
of vandetanib plus PTX was administered as two different sequences of
PTX administration: PTX administered 4 hours after the fifth dose
of vandetanib (vandetanib → PTX) or 24 hours before the first dose
of vandetanib (PTX → vandetanib).
For the subcutaneous model (8-10 mice per group), tumor growth
was measured with a vernier caliper, and the estimates of tumor weights
(mg = mm3) calculated as follows: (length [mm] × width [mm]2) / 2.
Efficacy of the treatment was expressed as best tumor growth inhibi-
tion [%T /C = (median tumor weight of treated tumors/median tu-
mor weight of control tumors) × 100] or tumor growth delay (T − C =
median time to reach 800 mg of treated tumor −median time to reach
800 mg of control tumor). Experiments were concluded when tu-
mors reached a median weight of 2 ± 0.5 g.
For the intraperitoneal model (orthotopic growth), 15 mice per
group were treated. At the end of the treatment period, five mice
per group were killed and necropsied to establish the tumor burden.
The remaining mice were monitored for tumor formation in the
peritoneal cavity (abdominal distension) and killed when they be-
came moribund (the day of death being considered the limit of
survival). At autopsy, the peritoneal cavity was macroscopically exam-
ined to ascertain the presence of tumor. Results are plotted as the
percentage survival against days after tumor transplant. The incre-
ment of life span (ILS) was calculated as 100 × [(median survival
day of treated group − median survival day of control group) / median
survival day of control group].
Statistical Analyses
Statistical analyses were carried out using Prism Software (Prism 5.01;
GraphPad Software, La Jolla, CA). Statistical differences for pharmaco-
dynamic, pharmacokinetic, and therapy experiments were evaluated by
two-way ANOVA followed by Bonferroni posttest; for the H33342
HPLC analyses, Student’s t test was used. Differences in survival were
analyzed by the log-rank test. P < .05 was considered significant.
Results
Effects of Vandetanib on Tumor Vasculature
Tumor microvessel density, dimension and maturation were mea-
sured after the administration of vandetanib (50 mg/kg per day or
vehicle control) for 5, 10, or 15 days to mice bearing A2780-1A9
tumor xenografts. As shown in Figure 1A, no significant difference
in tumor vessel density was detected (by CD31 staining) between the
vandetanib-treated group and the time-matched untreated control
group after 5, 10, or 15 days of continuous treatment. However,
mice treated with vandetanib had a reduction in tumor vessel dimen-
sions (vessel area and diameter) compared with the control animals,
which was evident after 10 and 15 days of vandetanib treatment
(Figures 1, B and C , and 2A). In the control group, vessel area
and diameter increased over time, whereas in the tumors from the
vandetanib-treated group, vessel area and diameter remained stable
or decreased slightly. A consistent decrease in large vessels percentage
(vessel area > 1000 μm2), rather than normal-sized vessels, was ob-
served in the tumors of vandetanib-treated animals at each time point
(data not shown). In contrast, we observed an increased vessel mat-
uration index, that is, pericyte coverage, which was statistically signif-
icant after 5 days of vandetanib pretreatment (Figures 1D and 2B).
Distribution of PTX in Tumor Xenografts Pretreated
with Vandetanib
To assess whether vandetanib pretreatment, and the associated vas-
cular changes, influenced tumor concentration of PTX, we studied
PTX distribution in A2780-1A9 tumor xenografts of animals that
had been pretreated with vandetanib (or its vehicle) for different pe-
riods and schedules (Figure 3).
In the first experiment, A2780-1A9 tumor-bearing mice were pre-
treated with vandetanib (or its vehicle) for 5 days (50 mg/kg per day).
Four hours after the last vandetanib dose, PTX (20 mg/kg) was ad-
ministered i.v., tumor and plasma samples were collected at 15 and
30 minutes and at 1, 3, 6 and 24 hours later, and PTX concentra-
tions in the samples were evaluated by HPLC.
As shown in Figure 3A, PTX distribution into the tumor tissue
was, in general, higher in the control group compared with in that
the vandetanib-pretreated groups, with the difference in mean PTX
tumor concentration between the groups reaching statistical signifi-
cance at 30 minutes and at 1 and 6 hours after PTX injection.
The tumor penetration of PTX in mice pretreated with vandetanib
was found to be slower than in the control mice as illustrated by the
Cmax and Tmax values (Table 1). Twenty-four hours after PTX admin-
istration, tumor PTX levels were not statistically different between the
two groups. PTX concentrations in plasma were comparable between
the two groups (Table 1).
To study the influence of the timing of vandetanib pretreatment on
PTX tumor uptake, in a second experiment, A2780-1A9 tumor-
bearing mice were pretreated with vandetanib for different periods
(1, 5, 10, and 15 days). Four hours after the last vandetanib dose,
PTX was administered, and its concentration was determined in
tumors and plasma 1 and 24 hours after its injection. As shown in
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Figure 3B, PTX tumor concentration was lower in the vandetanib-
pretreated group than in the control group at 1 hour after PTX
injection (starting from day 1), but at 24 hours after injection, con-
centrations were comparable between the two groups. To further
clarify whether this result was mediated by vandetanib, we evaluated
the impact of interrupting vandetanib pretreatment before PTX
administration. We confirmed that after 5 days of vandetanib treat-
ment, PTX tumor distribution was lower compared with controls
1 hour after PTX injection but comparable to controls 24 hours later
(Figure 3C.i). In mice in which vandetanib had been suspended
5 days before PTX administration, PTX tumor distribution was com-
parable to controls, at each time point (Figure 3C.ii). However, restart-
ing vandetanib treatment for 5 days after the 5-day interruption resulted
in a reduction in PTX tumor uptake once again 1 hour after PTX in-
jection (Figure 3C.iii). This indicates that the effect of vandetanib pre-
treatment on PTX distribution in the tumors is reversible.
Effect of Vandetanib on Vessel Perfusion by Hoechst 33342
To elucidate whether the reduced tumor distribution of PTX after
vandetanib pretreatment could be attributable to altered vessel per-
fusion, we measured perivascular Hoechst 33342 perfusion in tumors
of animals treated with vandetanib for 5 or 15 days. As shown in
Figures 2C and 4A, Hoechst 33342 staining around vessels was re-
duced in the vandetanib-treated group indicating decreased perfu-
sion even after 5 days of vandetanib treatment (the time point at
which vessel maturation index was higher than controls; Figure 1D).
To confirm this result, an experiment was performed measuring the
Hoechst 33342 content in the tumor by a quantitative HPLC assay.
Tumor-bearing mice were treated with vandetanib for 5, 10, or
15 days, including a 5-day interruption (Figure 4B). A statistically
significant decrease in Hoechst 33342 perfusion compared with the
control group was observed at all time points after vandetanib pre-
treatment. The 5-day interruption in vandetanib treatment allowed
complete recovery in vessel perfusion, with Hoechst 33342 perfusion
levels comparable with untreated controls. These results are in accor-
dance with the pharmacokinetic distribution of PTX.
Antitumor Activity of Vandetanib in Combination with PTX
To study whether the timing of vandetanib pretreatment associated
with modification at the tumor vasculature influenced the response to
PTX treatment, tumor-bearing mice were pretreated with vandetanib
for different periods (1, 5, or 10 days) before PTX. Figure 5A shows
that all the three combination schedules were more effective than
either agent alone (T /C = 40%, 57%, and 68% for the groups treated
Figure 1. Graphical presentation of image analysis of vascular structures in A2780-1A9 xenograft tumors from mice treated for 5, 10, or
15 days with vandetanib and in time-matched controls. Vessel density (A), vessel area (B), and vessel diameter (C) were quantitatively
assessed after immunostaining for CD31. Vessel maturation is given as the percentage of α-SMA/CD31 double-positive structures to all
vessels (D). Bars represents mean values ± SEM (n = 5 per group). *P < .05, **P < .01, ***P < .001 versus controls.
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for 1, 5, and 10 days, respectively, with vandetanib plus PTX vs PTX
alone), but no significant differences were observed among the three
combinations. The antitumor effects were greater when vandetanib
was administered after PTX (T /C = 21% vs PTX alone; Figure 5B)
compared with the reverse sequence (T /C = 57% vs PTX alone; Fig-
ure 5A.ii ). Mice were randomized on median tumor weight, aiming
to administer PTX when tumors reached the same size as those in the
vehicle-pretreated animals. To exclude the possibility that the better
response in the PTX→ vandetanib group might be due to the longer
treatment period, the experiment was repeated, randomizing the ani-
mals on the basis of tumor weight at the beginning of treatment for
both schedules. Similar results were observed with no advantage in
pretreating with vandetanib (data not shown).
To study whether the reduced tumor uptake of PTX after vandetanib
pretreatment affected the outcome to PTX plus vandetanib com-
bination therapy, we treated A2780-1A9 tumor-bearing mice for
5 days with vandetanib in combination with PTX, according to
two different sequences of PTX administration: PTX was adminis-
tered 4 hours after the fifth dose of vandetanib (vandetanib →
PTX; Figure 6A) or 24 hours before the first dose of vandetanib
(PTX → vandetanib; Figure 6B). These treatment schedules were
repeated for three cycles, with a 5-day break between cycles (as the
pharmacokinetic studies). As shown in Figure 6 (A and B), the
vandetanib plus PTX combination therapy was more effective than
either agent alone. Comparing the two combination sequences, ad-
ministering vandetanib after PTX (PTX → vandetanib, T /C =
17% vs PTX alone; Figure 6B) seemed more effective compared
with vandetanib administered before PTX (vandetanib → PTX,
T /C = 41% vs PTX alone; Figure 6A). Of note, the combination
sequence PTX → vandetanib enhanced the tumor growth delay
compared with single-agent treatment (T − C = 25 days vs 2
and 3 days for PTX and vandetanib, respectively), whereas in the
group receiving the vandetanib → PTX sequence, a slow but pro-
gressive growth was observed (T − C = 13 days). In both sequences,
tumors resumed their growth when treatment was suspended. Both
the single-agent treatments and the combination treatment sequences
were well tolerated, with no clinical signs or significant weight loss.
Because A2780-1A9 originated from an ovarian carcinoma, the ac-
tivity of the combination was assessed on the growth and spread of
the tumor in the peritoneal cavity [42]. Figure 6 (C and D) shows
that all vehicle-treated mice developed tumors, with a median sur-
vival time of 30 days. Paclitaxel and vandetanib increased the survival
of mice (ILS = 42% for PTX, ILS = 29% and 17% for vandetanib in
Figure 6, C and D, respectively). With both treatment sequences the
combination was more effective than either agent alone with a con-
sistent, although not significantly different, advantage when PTX
was given before vandetanib (vandetanib → PTX, ILS = 26% vs
PTX, ILS = 39% vs vandetanib, ILS = 80% vs vehicle, Figure 6C ;
Figure 2. Vessel analysis on cryosections of A2780-1A9 xenograft tumors in vandetanib-treated and time-matched control animals. Rep-
resentative images show differences in vessel morphology by CD31 staining (A), in vessel maturation by α-SMA (green)/CD31 (red)
double-immunofluorescence staining (B), and in vessel patency by Hoechst 33342 perfusion (blue, vessels in red; C).
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PTX → vandetanib, ILS = 33% vs PTX, ILS = 62% vs vandetanib,
ILS = 90% vs vehicle, Figure 6D). Macroscopic analysis of the tu-
mor burden in the peritoneal cavity of the mice at the end of treat-
ment confirmed the decreased tumor involvement after the treatment
with PTX or vandetanib as single agent (PTX more effective than
vandetanib); the reduction of tumor masses in mice treated with
the combinations was particularly evident, and only small tumor re-
siduals were detected at necropsy (data not shown). This observation
confirms the ability of the treatment to control tumor growth, which
resumes with the suspension of the therapy.
Discussion
Combining molecular-targeted agents with conventional chemother-
apy can result in improved efficacy [7]. Vandetanib is a tyrosine kinase
inhibitor of VEGFR-2, EGFR, and rearranged during transfection
signaling and is being evaluated in clinical trials both as monotherapy
and in combination with chemotherapy (including PTX) [39]. The
present study, conducted in a xenograft tumor model in nude mice,
shows the morphologic and functional changes in the tumor vas-
culature induced by vandetanib, the effect of vandetanib on the
intratumoral delivery of PTX, and the antitumor activity of PTX.
Consistent with previous observations, we have shown that the com-
bination of vandetanib plus PTX has greater antitumor activity than
single-agent treatment [36,44]. However, the changes in vascular
morphology and functionality induced by vandetanib treatment
were not associated with a direct increase in PTX delivery into the
tumor. Rather, our results suggest that the antitumor activity of the
vandetanib plus PTX combination is dependent, at least in part, on
drug sequence.
Vandetanib inhibits VEGF signaling, angiogenesis and tumor growth
[29]. In our model, we found that vandetanib reduced tumor vessel
dimension but did not alter tumor vessel density even in responsive tu-
mors. The relevance of vessel density as an indicator of antiangiogenic/
antitumor activity has been questioned, and vessel density has not always
Figure 3. PTX distribution in A2780-1A9 xenograft tumors of vandetanib-pretreated mice. (A) PTX distribution in tumors at 15 and 30 min-
utes and at 1, 6, and 24 hours of mice pretreated with vandetanib or with vehicle for 5 days. (B) PTX distribution in tumors at 1 and
24 hours of mice pretreated with vandetanib or vehicle for 1, 5, 10, or 15 days. (C) PTX distribution in tumors at 1 and 24 hours follow-
ing different schedules: i) vandetanib for 5 continuous days; ii) vandetanib for 5 days, an interruption of the treatment for 5 days; iii)
vandetanib for 5 days, followed by a 5-day treatment interruption, and vandetanib for a further 5 days. The arrow (↑) indicate the time at
which PTX was given. Values are reported as mean ± SD (n = 4 per group). *P < .05, **P < .01, ***P < .001 versus controls.
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Figure 4. Hoechst 33342 perfusion in vandetanib-pretreated A2780-1A9 tumor-bearing mice. (A) Tumor perfusion analyzed with confocal
laser scanning microscopy, after 5 and 15 days of vandetanib treatment. (B) Tumor perfusion was quantified with HPLC after 5, 10, or
15 days of vandetanib treatment and after 5 days of vandetanib treatment followed by a 5-day treatment interruption. Values are re-
ported as mean ± SEM (n = 4-5 per group). *P < .05, **P < .01 versus controls.
Figure 5. Antitumor activity of vandetanib plus PTX combination therapy on A2780-1A9 xenograft tumors. (A) Mice received vandetanib
(▵, 50 mg/kg per day), for 1 (i), 5 (ii), or 10 days (iii), and PTX (▴, 20 mg/kg) 4 hours after the last dose of vandetanib. (B) Mice received PTX
(▴, 20 mg/kg) followed by vandetanib (▵, 50 mg/kg per day for 5 days). Graphs are all from the same trial, referring to the same vehicle
and PTX (n = 8-10 per group). ***P < .001, versus PTX alone.
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been associated with antiangiogenic efficacy [45]. Indeed, changes in the
function of the tumor vascular bed might be more relevant indica-
tors of antiangiogenic activity [46].
Jain [19] proposed that the judicious application of antiangiogenic
agents may “normalize” the abnormal tumor vasculature, resulting in
a more efficient delivery of drugs and oxygen to the tumor. “Normal-
ization” has been defined as reversing the abnormalities of the vascu-
lar bed in the tumor: in the present study, vandetanib affected dilated
tumor vessels, increasing the proportion of mature vessels and de-
creasing vessel perfusion. In addition, the term “normalization” could
also be considered as an overall increase in the delivery of chemother-
apy during the “normalization window” [20–23]. However, in our
model, we observed decreased PTX delivery after vandetanib treat-
ment at early time points (1 hour after PTX) compared with control,
although similar tumor PTX levels were present in the vandetanib-
pretreated and the control animals at a later time point (i.e., 24 hours
after PTX). As plasma data exclude reduced drug availability, we hy-
pothesize that this could possibly be because PTX penetration on
tumor was less efficient because of the poorer perfusion in vandetanib-
treated animals. The association between vandetanib treatment and
reduced tumor delivery of PTX was further demonstrated by the ob-
servation that stopping vandetanib treatment restored PTX uptake by
tumor tissue to levels similar to the matched controls and, moreover,
that restarting vandetanib treatment resulted in a reduction of PTX
distribution to the tumor once again.
Increased delivery of chemotherapy after antiangiogenic therapy is
not a general finding. For example, although several preclinical stud-
ies have shown increased intratumoral drug uptake, after VEGF/
VEGFR antibody treatment (e.g., bevacizumab) [20,22,23], decreased
drug uptake has been observed with other inhibitors of angiogenesis,
including RTKIs (for review, see [28]). We believe that our findings
are not likely to be specific for PTX but rather reflect a decrease in
Figure 6. Antitumor activity of vandetanib in combination with PTX on A2780-1A9 tumor bearing mice subcutaneously (A and B) or in the
peritoneal cavity (C and D). Mice received vandetanib (▵, 50 mg/kg per day), PTX (▴, 20 mg/kg), or the combination for three cycles of
5 days. (A and C) Vandetanib→ PTX: PTX was administered 4 hours after the fifth dose of vandetanib. (B and D) PTX→ vandetanib: PTX
was administered 24 hours before the first dose of vandetanib. Mice were randomized to start PTX treatment when median tumor
weight matched in the two experimental settings (median = 150 mg, n = 8-10; A and B) or at 7 days after tumor transplantation
(n = 10; C and D). Graphs in A and B or in C and D are from the same trial, referring to the same vehicle and PTX. CR indicates com-
plete remission (mice remaining disease free for at least 4 weeks after the end of treatment). *P < .05, **P < .01, ***P < .001, versus
PTX alone.
Table 1. Main Pharmacokinetic Parameters of PTX Distribution in Plasma and Tumor Tissues of
Vandetanib Pretreated Mice.
Tissue Treatment Cmax (μg/g; μg/ml) Tmax (h) AUC (μg/g; μg/ml) T1/2 (h)
Tumor Control 5.9 1.00 100.6 29.80
Vandetanib 4.3 3.00 82.0 34.50
Plasma Control 30.1 0.17 26.1 0.52
Vandetanib 31.8 0.17 33.0 0.63
Experiment was performed as in Figure 3A.
AUC indicates area under the concentration versus time curve; Cmax, maximal drug concentration;
Tmax, time at which the Cmax was found; T1/2, terminal elimination half-life.
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tumor perfusion because Hoechst 33342 level, indicators of vascular
perfusion [47], was reduced in the tumors of mice pretreated with
vandetanib. A more detailed analysis of vessel and drug distribution
would be needed to determine the degree of heterogeneity that might
be hidden within an overall decreased perfusion over the whole tumor
[48]. For example, better-perfused vessels that remain after vandetanib
may allow increased delivery of PTX in certain regions of the tumor.
However, even if tumor vessels were “normalized” by vandetanib
in the current study, there seemed to be neither a clear efficacy ad-
vantage in pretreating with vandetanib before PTX nor a dependence
from the length of vandetanib pretreatment (Figure 5), the best anti-
tumor response being observed with the schedule of PTX adminis-
tered before vandetanib. This suggests that the overall therapeutic
response to RTKI plus chemotherapy combinations might be im-
proved by appropriate sequencing of the individual agents.
The scheduling of combination regimens that include a small-
molecule RTKI is often guided by in vitro studies. In the case of
vandetanib, differences in outcome of the in vitro and in vivo se-
quencing studies may be due to context-dependent effects of EGFR
andVEGFR inhibition in the different assay systems. EGFR-dependent
effects of vandetanib are likely to dominate in in vitro assays where
there is no role for VEGF-dependent new angiogenesis, whereas
VEGFR-2–dependent antiangiogenic effects of vandetanib may domi-
nate in vivo [35,44]. It is unlikely that the effects of vandetanib ob-
served in this study were mediated by effects on EGFR signaling
because A2780-1A9 cells did not respond, either in vitro or in vivo, to
gefitinib, a highly selective EGFR inhibitor (data not shown).
We used a schedule of 5 days of vandetanib treatment to allow
vandetanib to exert its effects on the tumor vasculature, followed
by a 5-day interruption in therapy to allow recovery of the vascular
bed and improved PTX distribution into the tumor. The different
response of the two sequences might reflect the distribution of PTX
in the tumor as previously discussed, although the tumor level of
PTX at 24 hours after its administration was comparable to controls.
The different response to the combination therapy is not influenced
by the size of the tumor at the beginning of the treatment with
PTX (same weight in the two schedules; Figure 6) or by the duration
of the treatment (same duration; data not shown). In fact, tumors
seemed to respond as long as the animals were treated, but when treat-
ment stopped, tumor growth resumed at a rate similar to untreated
controls. Further understanding of the therapeutic interaction be-
tween chemotherapy (i.e., PTX) and RTKI (i.e., vandetanib) may pro-
vide important explanations of the overall tumor response.
Also, in the orthotopic model of tumor spreading in the peritoneal
cavity, the combination of the two agents was able to control the tu-
mor growth only for the duration of the treatment (as confirmed by
necropsy of the mice at the end of treatment). In this setting, a clear
advantage with either one of the two sequences was not observed. We
recognize that there are limitations to this model. We have focused
on tumor masses spreading into the peritoneal sites, where angio-
genesis might not be predominant for their initial growth and
PTX distribution might not be influenced by modification of the
vasculature. Further studies on more complex models are necessary
to assess the relevance of these findings in ovarian carcinoma [49].
Nevertheless, the results of this study have potentially important im-
plications for the design of trials with agents that target multiple
growth factor pathways in combination with chemotherapy. They
indicate that the sequence of the drugs may be crucial in optimizing
tumor response during combination schedules. Robust tumor pharmaco-
dynamics and pharmacokinetics could assist the fine-tuning of drug
timing and sequences and might ultimately improve antitumor activity.
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Supplementary Data
Supplementary Information 1
Immunopathologic analyses. Cryosections (4 μm) were fixed for
1 minute in methanol and for 8 minutes in acetone at room tem-
perature and processed as follows.
Vessel density and morphology. Vessel density and morphology
were assessed by immunostaining with anti-CD31 antibody MEC13.3
(BecktonDickinsonGmbH,Heidelberg,Germany), a biotin-conjugated
mouse anti–rat immunoglobulin G subclass 1/2a monoclonal antibody
(clone G28-5; Beckton Dickinson GmbH), and the streptavidin-AP
reagent/chromogen of the Dako REAL Detection System AP/RED
(Dako Deutschland GmbH, Hamburg, Germany). Three randomly
selected measurement fields (0.94 mm2) from each tumor with the
highest vessel density (hot spots) were scanned, and all CD31-stained
vessel structures were marked by the examiner. The vessel density, ves-
sel area, and vessel diameter (represented by the shortest Feret’s diam-
eter) were determined using computer aided image analysis software
(AxioVision Rel. 4.6.2; Zeiss, Oberkochen, Germany).
Vessel maturation index. Vessel maturation was assessed by
quantification of blood vessels showing colocalization of α-SMA and
CD31-positive cells. Sections were stained with anti-CD31 antibody
MEC13.3 visualized with a Cy3-conjugated goat anti-rat immuno-
globulin G/immunoglobulinM serum (Dianova, Hamburg, Germany)
followed by incubation with a biotinylated anti–α-SMA antibody
(clone 1A4; Dako Deutschland GmbH). Biotinylation was performed
using the Animal Research Kit (Dako Deutschland GmbH) follow-
ing the manufacturer’s instructions. Biotinylated antibodies were de-
tected with fluorescein isothiocyanate–conjugated streptavidin (Dako
Deutschland GmbH). Double immunofluorescence was analyzed by
confocal laser scanning microscopy (cLSM; LSM510, Zeiss) as recently
described [1]. From each tumor, five randomly selected measurement
fields of 0.2 mm2 were scanned, and all CD31-stained vessels and all
CD31/α-SMA double-positive vessels were counted. Vessel maturation
index was represented asα-SMA–positive vessels as a percentage of total
CD31-positive vessels.
Vessel perfusion. Sections of Hoechst 33342 perfused tumors
were CD31 stained for immunofluorescence microscopy as previ-
ously described. Immediately after immunostaining, sections were
analyzed with the cLSM. Four randomly selected vascularized areas
of each tumor (detection area, 0.21 mm2) were scanned: for CD31
fluorescence scanning the HeNe (543 nm) laser was combined with
the light filter LP 560 (Zeiss). The Hoechst 33342 fluorochrome
was excited using an HBO mercury lamp (OSRAM GmbH, Berlin,
Germany), and the emitted fluorescence light was detected.
A detection level for blue pixels (Hoechst fluorescence intensity)
was defined using tumors with low and highly patent vessels. The
pixel number and pixel area were automatically calculated in all
images using the colocalization analysis software tool of cLSM. Sub-
sequently, the blue pixel area was set in percent of the whole scanned
area. The mean value and SEM of the blue pixel area were calculated
using the images of all animals per group.
To confirm the cLSM result, Hoechst 33342 levels in tumors were
also quantified by HPLC analysis. Briefly, tumor samples were ho-
mogenized in CH3CN (1:2 wt/vol) and 0.2 ml of the homogenate
added with 20 μl of SN38 (2 μM) as internal standard. Samples
were centrifuged at 13,000 rpm for 10 minutes, and 150 μl of the
organic phase was added with 150 μl of 0.2 M ammonium acetate
buffer pH 5 and injected in the HPLC. Chromatographic separation
was carried out on Symmetry Shield RP18 (3.5 μm, 4.6 × 150 mm)
column (Waters, Millford, MA) and gradient elution from 0.1 M
CH3COOH pH 5/CH3CN/CH3OH 80:10:10 to 35:20:45 during
a 20-minute period. The flow rate was of 1 ml/min. Fluorimetric
detection was performed at λex = 376 nm and λem = 534 nm.
Supplementary Information 2
Pharmacokinetic analysis
Plasma PTX assays. Plasma samples (0.3 ml) were spiked with
1 μg of docetaxel (Indena S.p.A.) as internal standard and 200 μl of
0.2 M ammonium acetate buffer pH 5 was added. After centrifuga-
tion, supernatants were processed using a Rapid Trace SPE work-
station (Zymark, Hopkinton, MA), with Sep-Pak CN cartridge for
solid-phase extraction (Waters). PTX was eluted from the columns
with 1 ml of 0.1% triethylamine in CH3CN. The eluents were dried
under nitrogen, and the residues were reconstituted in 120 μl of mo-
bile phase and injected into the HPLC system. Chromatographic
separation was carried out on Novo Pak C18 (3.9 × 150 mm) col-
umn (Waters) and isocratic mobile phase of 0.01 M CH3COONH4
pH 5/CH3CN/CH3OH/THF 59:34:6:1 with a flow rate 1.3 ml/min.
UV detection was performed at 230 nm (2462 Dual λ Absorbance
Detector; Waters). Control mouse plasma was used to prepare a cali-
bration curve over the range 0.33 to 16.7 μg/ml of PTX.
Tumor PTX assays. Tumor samples were homogenized in 0.2 M
CH3COONH4 pH 5 (1:4 wt/vol), and 1 ml of homogenate sample
was added with 1 μg of IDN5390 (Indena S.p.A.) as internal stan-
dard and extracted with 5 ml of CH3CN. Samples were centrifuged
at 4000 rpm for 10 minutes. The organic phase was separated and
dried under nitrogen, and the residues were dissolved with 120 μl
of mobile phase and 30 μl of SSA 1% (wt/vol). One hundred micro-
liters of the reconstitute samples was injected in the HPLC and ana-
lyzed with a Symmetry C18 (3.5 μm, 4.6 × 150 mm) column (Waters)
using a mobile phase of CH3CN/0.01 M CH3COONH4 pH 5/
CH3OH 39:51:10, a flow rate of 1.3 ml/min, and UV detection at
230 nm. Tissues obtained from control mice were used to prepare
the calibration curve by the addition of PTX.
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